Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Anavex Reports ANAVEX 2-73 Results in Preclinical Model of Alzheimer’s Disease

Published: Monday, November 04, 2013
Last Updated: Monday, November 04, 2013
Bookmark and Share
ANAVEX 2-73 dose-dependently blocks Tau and amyloid-beta (“amyloid”) proteins and memory deficit in a mouse model of Alzheimer’s disease (AD).

A reduction in these two main hallmarks of Alzheimer’s has the potential to stop, slow or reverse the disease.  The report also suggests that, because it is targeting the mixed muscarinic and Sigma-1 receptors, ANAVEX 2-73 is able to achieve its effect further “upstream” in the Alzheimer’s disease cascade.  This compares to most other current AD clinical development compounds that are mainly downstream and single-targeted approaches, which might be limited by adverse effects.  More interestingly, the mixed muscarinic and Sigma-1 agonist ANAVEX 2-73 exhibited powerful effects despite its moderate affinity for these receptors, emphasizing its great advantage for potential therapy in Alzheimer’s disease.

Tangui Maurice, PhD, CNRS Research Director, Head of Team 2 ‘Endogenous Neuroprotection in Neurodegenerative Diseases’, at the University of Montpellier and INSERM, and one of the study authors, said, “ANAVEX 2-73 also dose-dependently reduced C99 levels in the hippocampus, an effect which researchers are currently trying to achieve with BACE inhibitors.  In the mouse model we also confirmed the central role of the kinase GSK-3 beta in Alzheimer’s disease toxicity through drugs acting either directly as GSK-3 beta inhibitors, or indirectly, as mixed muscarinic and Sigma-1 ligands. Both can efficiently alleviate these two major alterations observed in the Alzheimer’s animal model, as well as in Alzheimer’s patient brains. However, by targeting GSK-3 beta indirectly as ANAVEX 2-73 does through muscarinic and Sigma-1 ligands, we could avoid the toxicity seen by directly targeting GSK-3 beta.”

Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, said, “Using further upstream targets that efficiently block tau phosphorylation and amyloid overproduction might be a more comprehensive approach in successfully treating this complex disease. Together with previously confirmed findings demonstrating the ability of ANAVEX 2-73 to reduce mitochondrial oxidative stress, this publication strengthens the case for a potential pharmacological treatment for Alzheimer’s disease.”

The report, entitled “Blockade of Tau Hyperphosphorylation and Amyloid-beta1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and Sigma-1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease,” is based on a scientific study conducted in France at the University of Montpellier and INSERM.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!